AbbVie

OCT tops the list of the leading CROs in 3Q 2017

Thursday, November 2, 2017

According to the Synergy Research Group report, the most active CRO in the region were OCT, Quintiles, PSI, Synergy Research Group and IPHARMA. OCT has been working with the largest number of patients during this period. AbbVie tops the list of the leaders among foreign pharmaceutical companies, which initiated clinical trials in 3Q, while Biocad and Severnaya Zvezda were named the most active among Russian companies.

[Read More]

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Crohn’s & Colitis Foundation launches IBD Clinical Trials Community

Monday, July 24, 2017

Clinical trial recruitment is a challenging step toward FDA approval of new treatments for patients across all disease states; this is especially true for inflammatory bowel diseases (IBD). The Crohn’s & Colitis Foundation launched a dedicated Clinical Trials Community for IBD. The Community is designed to educate patients, caregivers, and healthcare providers about the clinical trial process, its value, and how to address barriers that exist in enrollment.

[Read More]

Improved perception of the industry

Monday, June 12, 2017

The 2017 Global Pharmaceutical Reptrak study, prepared each year by Boston’s Reputation Institute, showed that the public’s perception of the pharmaceutical industry has improved, earning an industry score of 71.8, up from 68.2 in 2016. Furthermore, about 44% of respondents viewed the industry as having an excellent reputation, a seven point increase since 2016. Similarly, the number of respondents who perceived the industry as weak or poor declined, moving to 26% from 35% in 2016.

[Read More]

AbbVie reported Imbruvica CLL/SLL data

Wednesday, May 17, 2017

AbbVie, a global biopharmaceutical company, announced results from an analysis of data pooled from three phase III studies evaluating Imbruvica (ibrutinib) use in patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): RESONATE, RESONATE-2 and HELIOS.

[Read More]

AbbVie announces IIb data of elagolix for heavy menstrual bleeding

Tuesday, April 11, 2017

AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, announced detailed results from a phase IIb clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy (estradiol/norethindrone acetate) compared to placebo. The data demonstrated that elagolix, with and without add-back therapy, met the primary efficacy endpoint of reduced heavy menstrual bleeding as compared to placebo (p<0.001). These results were shared for the first time in an oral presentation at the third Congress of the Society of Endometriosis and Uterine Disorders (SEUD) in Singapore.

[Read More]

AbbVie joins ORIEN Avatar Research Program

Wednesday, March 29, 2017

AbbVie, a global biopharmaceutical company, and M2Gen, a health informatics solutions company, announced that AbbVie has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials.

[Read More]

Dementia Consortium funds dementia treatments team

Wednesday, March 15, 2017

The Dementia Consortium, a public-private partnership initiative bridging the gap between academic research and the pharmaceutical industry, is supporting a project led by Dr. David Brough at the University of Manchester to develop novel therapeutics for Alzheimer’s disease targeting the immune system. This is the fifth project supported by the Dementia Consortium, and has been awarded £191,757 by the initiative.

[Read More]

Novo Nordisk, Servier, Otsuka, Teva among top sponsors

Wednesday, March 1, 2017

Sponsors have done a good job of maintaining, but not improving, the overall quality of their relationships with investigative sites during the past two years, according to a new CenterWatch survey, but performance gaps have widened across several of the attributes sites identify as the most important for conducting a successful study.

[Read More]